Education
About Us
Working with TipRanks
Follow Us
Opthea Limited Sponsored ADR (OPT)
NASDAQ:OPT
RESEARCH TOOLSreports
OPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.79 - $6.30
Previous CloseN/A
Volume12.29K
Average Volume (3M)11.89K
Market Cap
$469.72M
Enterprise Value$191.88M
Total Cash (Recent Filing)$12.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 28, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding153,910,920
10 Day Avg. Volume0
30 Day Avg. Volume11,887
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4209.28
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.54K
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
$4.25Price Target Upside32.81% Upside
Rating ConsensusHold
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Bears Say
Clinical TrialsThe Phase 3 COAST trial of sozinibercept in combination with Eylea in wet age-related macular degeneration failed to meet its primary endpoint.
Financial SolvencyThe company could be required to pay four multiples of the amounts paid to the company upon termination of the DFA agreement, which would have a material impact on the solvency of the company.
Stock DowngradeGiven the negative readout, the stock has been downgraded to MP and the price target moves from $12 to $1.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
3.33% Other Institutional Investors
96.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
OPT FAQ
What was Opthea Limited Sponsored ADR’s price range in the past 12 months?
Opthea Limited Sponsored ADR lowest stock price was $1.79 and its highest was $6.30 in the past 12 months.
What is Opthea Limited Sponsored ADR’s market cap?
Opthea Limited Sponsored ADR’s market cap is $469.72M.
When is Opthea Limited Sponsored ADR’s upcoming earnings report date?
Opthea Limited Sponsored ADR’s upcoming earnings report date is Aug 28, 2025 which is in 132 days.
How were Opthea Limited Sponsored ADR’s earnings last quarter?
Opthea Limited Sponsored ADR released its earnings results on Feb 27, 2025. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.75.
Is Opthea Limited Sponsored ADR overvalued?
According to Wall Street analysts Opthea Limited Sponsored ADR’s price is currently Undervalued.
Does Opthea Limited Sponsored ADR pay dividends?
Opthea Limited Sponsored ADR does not currently pay dividends.
What is Opthea Limited Sponsored ADR’s EPS estimate?
Opthea Limited Sponsored ADR’s EPS estimate is -0.29.
How many shares outstanding does Opthea Limited Sponsored ADR have?
Opthea Limited Sponsored ADR has 153,910,920 shares outstanding.
What happened to Opthea Limited Sponsored ADR’s price movement after its last earnings report?
Opthea Limited Sponsored ADR reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -2.609%.
Which hedge fund is a major shareholder of Opthea Limited Sponsored ADR?
Currently, no hedge funds are holding shares in OPT
---
Opthea Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.25 (32.81% Upside)
$4.25 (32.81% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.45%
Trailing 12-Months
Company Description
Opthea Limited Sponsored ADR
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
---
OPT Stock 12 Month Forecast
Average Price Target
$4.25
▲(32.81% Upside)
Technical Analysis
Cormedix
―
Sinovac Biotech
―
Urogen Pharma
―
Arvinas Holding Company
―
Cullinan Management
―
Best Analysts Covering OPT
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
-1.86%
reiterated a buy rating 7 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -1.86% per trade.
---